2) Rozanolixizumab is a monoclonal antibody that targets the neonatal Fc receptor (FcRn). This receptor normally protects antibodies from breakdown, so blocking it leads to a reduction in antibodies.
The drug is already approved as a treatment for myasthenia gravis.
